OCA
SPRY icon

Octagon Capital Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Octagon Capital Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,350,000
Closed -$23.6M – 30
2025
Q2 		$23.6M Buy
1,350,000
+725,000
+116% +$10.5M 5.17% 5
2025
Q1 		$7.86M Buy
+625,000
New +$7.52M 1.52% 25

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Octagon Capital Advisors's SPRY Position: Q3 2025 in Review

Octagon Capital Advisors sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 1,350,000 shares — an estimated $23.6M sold.

Octagon Capital Advisors first reported a position in SPRY in Q1 2025 and held it in 2 quarters. The position peaked at $23.6M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Octagon Capital Advisors reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,350,000 ARS Pharmaceuticals shares in Q3 2025, an estimated $23.6M.
  • Octagon Capital Advisors first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Octagon Capital Advisors's ARS Pharmaceuticals position peaked at $23.6M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Octagon Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.